Table 1.
Baseline demographic and clinical characteristics of patients
| Characteristic | Category | Cd 20/70 mg/m2 (N = 6) |
|---|---|---|
| Gender | Male | 4 (66.7) |
| Female | 2 (33.3) | |
| Age (years) | Median (range) | 68.0 (63‐80) |
| ECOG performance status | 0 | 5 (83.3) |
| 1 | 1 (16.7) | |
| ISS Stage | 1 | 1 (16.7) |
| 2 | 2 (33.3) | |
| 3 | 3 (50.0) | |
| Presence of neuropathy | Yes | 6 (100.0) |
| Severity of neuropathya | Grade 1 | 4 (66.7) |
| Grade 2 | 2 (33.3) | |
| Number of prior treatments (number of times) | Median | 4.5 (4‐8) |
| 4 | 3 (50.0) | |
| 5 | 1 (16.7) | |
| ≥6 | 2 (33.3) | |
| High‐risk cytogeneticsb | Yes | 1 (16.7) |
| No | 4 (66.7) | |
| Unevaluable | 1 (16.7) | |
| Plasma cell ratio in bone marrow (%) | Median | 10.80 |
| Hemoglobin (g/dL) | Median | 10.30 |
| <10.5 | 3 (50.0) | |
| ≥10.5 | 3 (50.0) | |
| Neutrophil count (/mm3) | Median | 1689.5 |
| <1500 | 2 (33.3) | |
| ≥1500 | 4 (66.7) | |
| Lymphocyte count (/mm3) | Median | 1164.3 |
| <800 | 1 (16.7) | |
| ≥800 | 5 (83.3) | |
| Platelet count (104/mm3) | Median | 13.80 |
| <15 | 3 (50.0) | |
| ≥15 | 3 (50.0) |
Data in the table are presented as n (%), unless otherwise indicated.
Cd, carfilzomib and dexamethasone; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.
a
In the case of more than 1 neuropathy, the most severe was reported.
b
High‐risk cytogenetics were defined as positive for del(17p) in ≥20% of screened plasma cells, t(4;14), t(14;16), or hypodiploidy.